Amarin Corporation PLC

AMRN

NASDAQ. Currency in USD

1.19 -0.07 ( -5.56% )

Real time prices: December 19

Market Cap.
480.56M
Beta (5Y monthly)
1.78
Price/Earnings
-
EPS (TTM)
-0.16
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
2.00M
1y Target Est.
3.33
Day's Range
1.18
-
1.26
52 Week's Range
1.04
-
3.81

Historical Summary

Performance
EPS growth
Share Buybacks

About Amarin Corporation PLC

Sector
Healthcare
Industry
Biotechnology
Website
https://www.amarincorp.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
397.01M
Employees
560
Address
Grand Canal Docklands, Dublin, Ireland, 2
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Latest news

Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland

-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course...
By GlobeNewswire Inc. - 8 weeks ago

Why Amarin (AMRN) Stock Might be a Great Pick
Why Amarin (AMRN) Stock Might be a Great Pick

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs...
By Zacks Investment Research - 10 weeks ago

Why Amarin Stock Was a Winner Today
Why Amarin Stock Was a Winner Today

The product most readily identified with the company will soon hit pharmacy shelves in Australia.
By The Motley Fool - 11 weeks ago

Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia

-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated...
By GlobeNewswire Inc. - 11 weeks ago

Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named
Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named

The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously...
By Zacks Investment Research - 12 weeks ago

Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark
Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark

Apellis' (APLS) earnings miss estimates in the third quarter of 2022 while revenues beat the...
By Zacks Investment Research - 12 weeks ago

Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 66.5% to settle at $29.10 on...
By Benzinga - 12 weeks ago

Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session

Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. Veru Inc. (NASDAQ: VERU)...
By Benzinga - 12 weeks ago